Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SBC Medical Group Holdings Incorporated (SBCWW)
Irvine, CA, US
SBC Medical Group Holdings Incorporated (SBCWW) specializes in providing comprehensive management and support services to a network of aesthetic treatment centers. The company operates globally, with a significant presence in Japan, Vietnam, and the United States, alongside its other international activities. SBC's service portfolio for its franchisee clinics is extensive, covering everything from strategic advertising and marketing campaigns to human resources management, including staff recruitment and professional training programs. They also manage booking reservations for clients, assist with employee housing and facility rentals, and oversee the entire process of clinic construction and design. Furthermore, SBC facilitates the procurement of essential medical equipment and consumable supplies. In addition to these foundational services, SBC Medical Group offers advanced IT software solutions and a diverse range of cosmetic and reconstructive medical procedures. These treatments encompass common aesthetic enhancements such as breast augmentation, liposuction, and various rejuvenation therapies designed to address wrinkles, acne, scars, cellulite, excess fat, skin discoloration, and other visible signs of aging. Specialized services include laser skin toning and spot removal, double eyelid surgery, rhinoplasty (nose reshaping), and treatments for osmidrosis and hyperhidrosis. The company also provides hair transplants, gynecological formation treatments, laser hair removal, facial contouring surgeries, cosmetic dental procedures, and tattoo removal. Ophthalmic interventions like LASIK eye surgery and lateral canthoplasty are offered, alongside brow lifts, androgenetic alopecia (male pattern baldness) treatment, and methods for preventing cheek sagging. Established in 2000, the company maintains its corporate headquarters in Irvine, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.15% | -2.83% | -6.43% | -29.06% | +22.17% | -2.66% | +22.17% | +238.31% | +238.31% | +238.31% | +238.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Consulting Services: +8.7%-15.5% Q1'26: -19.8% (vs Q1'25)
-
EPS growth Consulting Services: +10.0%+4.2% Q1'26: -47.6% (vs Q1'25)
-
FCF margin FCF growth · Consulting Services: +16.4%+22.5% Q1'26: +24.0% (vs Q1'25)
-
EBIT margin Consulting Services: +14.1%+47.4% ★ Q1'26: +46.7% (vs Q1'25)
-
ROIC Consulting Services: +12.0%+33.9% ★ Q1'26: +34.5% (vs Q1'25)
-
Share dilution Consulting Services: +0.6%+6.7% Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Consulting Services: -0.79×0.61× ★ Q1'26: 0.29× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
205.42M
est: 217.84M (-5.7%)
|
173.61M
est: 179.48M (-3.3%)
|
179.37M
173.89M – 182.07M
-0.1% YoY
|
194.95M
183.68M – 202.28M
+8.7% YoY
|
199.05M
190.13M – 204.40M
+2.1% YoY
|
| EBITDA |
77.28M
est: 75.93M (+1.8%)
|
84.91M
est: 62.56M (+35.7%)
|
62.52M
60.61M – 63.47M
-0.1% YoY
|
67.95M
64.02M – 70.51M
+8.7% YoY
|
69.38M
66.27M – 71.25M
+2.1% YoY
|
| EBIT |
73.48M
est: 68.78M (+6.8%)
|
82.23M
est: 56.67M (+45.1%)
|
56.64M
54.91M – 57.49M
-0.1% YoY
|
61.55M
58.00M – 63.87M
+8.7% YoY
|
62.85M
60.03M – 64.54M
+2.1% YoY
|
| Net Income |
46.61M
est: 60.77M (-23.3%)
|
50.99M
est: 47.06M (+8.4%)
|
46.78M
44.05M – 48.41M
-0.6% YoY
|
50.52M
47.58M – 52.29M
+8.0% YoY
|
51.96M
48.93M – 53.78M
+2.9% YoY
|
| SGA |
70.69M
est: 85.37M (-17.2%)
|
59.80M
est: 70.34M (-15.0%)
|
70.29M
68.15M – 71.35M
-0.1% YoY
|
76.40M
71.98M – 79.27M
+8.7% YoY
|
78.01M
74.51M – 80.10M
+2.1% YoY
|
| EPS |
0.48
est: 0.59 (-18.6%)
|
0.50
est: 0.46 (+9.4%)
|
0.45
0.43 – 0.47
-0.6% YoY
|
0.49
0.46 – 0.51
+8.0% YoY
|
0.50
0.48 – 0.52
+2.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 5/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 5/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 5/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 5/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 5/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 5/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-22 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-20 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-17 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-16 | A | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yoshiyuki Aikawa | Chairman & Chief Executive Officer | 15M | — |
| Yuya Yoshida | Chief Operating Officer, Chief Financial Officer & Director | 304.4K | male |
| Ryoji Murata | Principal Accounting Officer | 137.0K | male |
| Miki Yamazaki | Chief Strategy Officer | — | female |
| Akiko Wakiyama | Chief Public Relations Officer | — | female |
| Shinya Inoue | Chief Marketing Officer | — | male |
| Taiki Sakaguchi | CHRO, Chief Planning Officer & Corporate Secretary | — | — |
| Shengfu Hsiao | Chief Technology Officer | — | male |
| Hiroyuki Miya | Chief Operating Officer of SBC Medical Group Co., Ltd. (Japan) | — | male |
| Kazuki Ichimori | Chief Corporate Development Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SBCWW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
